贝派地酸在血脂异常和他汀类药物不耐受患者中的应用进展

血浆低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)升高是公认的动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ACSVD)的危险因素之一.目前用于治疗高LDL-C血症的主要药物为他汀类药物,其他可选药物包括...

Bempedoic acid in the treatment of patients with dyslipidemias and statin intolerance

An elevated plasma level of low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor of atherosclerotic cardiovascular disease (ACSVD). Randomized studies with statins alone or plus other lipid-lowering agents have demonstrated their clinical efficacy in lowering LDL-C. Several classes of new non-statin agents have been successfully developed[e.g., ezetimibe and inhibitors of proprotein convertase subtilisin/kexin type 9(i-PSCK9)]. However, many high-risk ACSVD patients might benefit from these drugs and at least 10% of them were statin intolerant. As a new inhibitor of cholesterol synthesis, bempedoic acid (ETC-1002) targets ATP citrate lyase (ACL). Importantly, ETC-1002 is only converted into an active form in liver and thus lacks muscular side effects. This review summarized the latest advances of applying bempedoic acid in patients with dyslipidemia and statin intolerance. And mechanism of action, pharmacokinetics, efficacy, safety and tolerance of bempedoic acid were also discussed.